Syngene
Putting Science to Work

Syngene International

Q1 FY27 Earnings Call

July 30, 2026

Safe Harbor Statement

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.

Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts, our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India.

Neither the Company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

Executive Chairperson
Remarks

Kiran Mazumdar-Shaw

Executive Chairperson
Syngene International Limited

Executive Chairperson Remarks

FY27 – Transition year:

- FY27 is a year of course correction, strategic renewal and disciplined execution under a new leadership team
- Focused on restoring sustainable, profitable growth
- Building a more diversified and resilient commercial portfolio

Strategic Priorities:

- Build a stronger commercial engine through deeper customer relationships, strategic partnerships and focused business development
- CDMO critical for long-term growth
- Expand differentiated discovery capabilities
- Large molecule CDMO remains one of Syngene's strongest strategic differentiators

Outlook:

- Single-digit revenue decline expected in FY27 (Rs. terms); EBITDA margins expected in the mid-20s
- Focus on restoring commercial momentum, improving asset utilisation and driving operational efficiency
- Return to profitable and sustainable growth from FY28 onwards

CEO
Remarks

Siddharth Mittal
Managing Director & CEO
Syngene International Limited

MD and CEO Remarks

The CRDMO industry continues to present significant opportunities for long-term growth, and Syngene's strong scientific foundation, differentiated capabilities and trusted customer relationships position us well to capture them.

Immediate focus: Sharpening commercial execution, strengthening execution across our businesses and building a more agile, cost-competitive organisation

Continuing investments in Discovery and CDMO capabilities, AI, digital technologies and differentiated scientific expertise to deliver greater value for customers and strengthen our competitive position

Q1 FY27: Business highlights

Signed an MoU with the Translational Health Science and Technology Institute, Govt. of India, to support early-phase clinical development, translational research, and First-in-Human (FIH) and Phase I studies.

Enhanced Syn.AI with gigascale virtual screening and AI-driven de novo molecule design capabilities to accelerate drug discovery.

Recognized in TIME Magazine and Statista's World's Most Sustainable Companies 2026 ranking for the second consecutive year.

Q1 FY27: Performance

Revenue from Operations

Rs. 736 Cr (*-16%* Y-o-Y)

Operating EBITDA & Margin

Operating EBITDA Rs. 91 Cr

Operating EBITDA Margin 12%

PAT

- Before exceptional item: Rs. 1 Cr
- After exceptional item: Rs. -9 Cr

Sales Split (Q1 FY27)



Capex

Q1 capex of Rs. 70 Cr

- Bayview facility in the U.S.
- Technology platforms and automation
- AI capabilities and strategic priorities

Net cash balance of Rs.1,541 Cr

Despite the near-term challenges, our balance sheet remains strong

We will continue to make investments through the year primarily in operationalizing Bayview, expanding our capability builds and advancing new modalities to drive future growth

Closing remarks

- Our priorities are clear
- Focus now is executing consistently, enhancing operational performance and delivering better outcomes for our customers

Q&A

Syngene

Putting Science to Work